Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | F3 | P13726 | 2/20 | 0.69 |
| ▸ | CXCL12 | P48061 | 3/20 | 0.69 |
| ▸ | MAOB | P27338 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.68 |
| ▸ | MITF | O75030 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | GUSB | P08236 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25199743 | 1.00 | PTGS2 (0.69) | PTGS2F3CXCL12MAOBMAPT | |
| SCHEMBL31233368 | 1.00 | PTGS2 (0.69) | PTGS2F3CXCL12MAOBMAPT | |
| SCHEMBL7304255 | 1.00 | PTGS2 (0.69) | PTGS2F3CXCL12MAOBMAPT | |
| SCHEMBL30383198 | 1.00 | PTGS2 (0.69) | PTGS2F3CXCL12MAOBMAPT | |
| SCHEMBL7306057 | 0.90 | F3 (0.69) | PTGS2F3CXCL12MAOBMAPT | |
| SCHEMBL7312933 | 0.90 | F3 (0.69) | PTGS2F3CXCL12MAOBMAPT | |
| SCHEMBL25200404 | 0.89 | BACE1 (0.68) | F3CXCL12MAOBMAPTRAB9A | |
| SCHEMBL30383358 | 0.89 | BACE1 (0.68) | F3CXCL12MAOBMAPTRAB9A | |
| SCHEMBL25198501 | 0.89 | BACE1 (0.68) | F3CXCL12MAOBMAPTRAB9A | |
| SCHEMBL1225523 | 0.89 | PTGS2 (0.71) | PTGS2CXCL12MAOBCYP3A4CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-117304033-A | Caffeic acid derivative and preparation method thereof, pharmaceutical composition and application | 中国医学科学院药物研究所 | 2023-12-29 | — | — | CN | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2008016738-A2 | ANTIBACTERIAL AGENTS AND RELATED SCREENING METHODS USING SMALL MOLECULE MACROARRAYS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-0947494-A1 | Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity | F. HOFFMANN-LA ROCHE AG (CH) | 1999-10-06 | — | — | EP | disclosed |
| EP-0947511-A1 | Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity | F. HOFFMANN-LA ROCHE AG (CH) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | PTGS2 704/4885F3 5/4885CXCL12 399/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | PTGS2 330/4885F3 11/4885CXCL12 287/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | PTGS2 330/4885F3 11/4885CXCL12 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.